Since its discovery as a CDKI (cyclin-dependent kinase inhibitor) in 1993, the tumor
suppressor p16 (INK4A/MTS-1/CDKN2A) has gained widespread importance in cancer. The …

In late 1993 and early 1994, two distinct lines of research converged on a new tumor
suppressor gene located on human chromosome 9p21. The órst report was of the existence …

Osteosarcoma is a primary bone malignancy with a particularly high incidence rate in
children and adolescents relative to other age groups. The etiology of this often aggressive …

Since its discovery as an inhibitor of cyclin-dependent kinases 4 and 6, the tumor
suppressor p16 has continued to gain widespread importance in cancer. The high frequency …

Osteosarcoma is the most common nonhematologic malignancy of bone in children and
adults. The peak incidence occurs in the second decade of life, with a smaller peak after age …

Osteosarcoma is the most common primary malignant tumor of bone. Analysis of familial
cancer syndromes and sporadic cases has strongly implicated both p53 and pRb in its …

Both genetic and epigenetic changes contribute to development of human cancer.
Oncogenomics has primarily focused on understanding the genetic basis of neoplasia, with …

Inhibitors of DNA binding (IDs) antagonize basic-helix-loop-helix (bHLH) transcription
factors to inhibit differentiation and maintain stem cell fate. ID ubiquitination and proteasomal …

CDKN2A, the gene encoding the cell-cycle inhibitor p16 CDKN2A, was first identified in
1994. Since then, somatic mutations have been observed in many cancers and germline …

In this Update, the cytogenetic and molecular genetic findings in osteosarcoma (OS) and
some related tumors published since our book appeared in 1994 [1] will be presented and …